专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US5661153A 1-arylpyrimidine derivatives and pharmaceutical use thereof 失效
标题翻译： 1-芳基嘧啶衍生物及其药物用途
公开(公告)号：US5661153A
公开(公告)日：1997-08-26
申请号：US463277
申请日：1995-06-05
申请人： Yoshiaki Isobe , Toshimasa Katagiri , Junko Umezawa , Yuso Goto , Masashi Sasaki , Nobuo Watanabe , Hideharu Sato , Fumihiro Obara
发明人： Yoshiaki Isobe , Toshimasa Katagiri , Junko Umezawa , Yuso Goto , Masashi Sasaki , Nobuo Watanabe , Hideharu Sato , Fumihiro Obara
IPC分类号： C07D239/54 , C07D239/545 , C07D473/04 , C07D473/06 , A61K31/52
CPC分类号： C07D239/545 , C07D473/04 , C07D473/06
摘要： The present invention relates to 1-arylpyrimidine derivatives represented by general formula (I): ##STR1## wherein R.sub.1 is H, alkyl or aralkyl;Ar is 1-naphthyl, or a substituted or unsubstituted phenyl group;R.sub.4 is a substituted phenyl, a substituted styryl, 1-methylcyclohexyl, 4-methylcyclohexyl, 4-oxo-4H-pyran-2-yl or 2-oxo-2H-pyran-5-yl group;R.sub.5 and R.sub.6 are each independently H or alkyl;R.sub.3 is H, and R.sub.7 and R.sub.8 are combined together to be oxo, or else R.sub.3 and R.sub.7 are combined together to be another direct bond, and R.sub.5 and R.sub.8 are combined together to be a direct bond,or pharmaceutically acceptable salts thereof; and methods for treating allergic diseases with such compounds.
摘要翻译：本发明涉及由通式（I）表示的1-芳基嘧啶衍生物：Ar是1-萘基或取代或未取代的苯基; R4是取代的苯基，取代的苯乙烯基，1-甲基环己基，4-甲基环己基，4-氧代-4H-吡喃-2-基或2-氧代-2H-吡喃-5-基; R5和R6各自独立地为H或烷基; R3为H，R7和R8组合在一起为氧代，或者R3和R7组合在一起成为另一个直接键，R5和R8组合在一起成为直接键，或其药学上可接受的盐; 以及用这些化合物治疗过敏性疾病的方法。

32. 发明授权

US08433922B2 System and method of biometric authentication using multiple kinds of templates 失效
标题翻译：使用多种模板的生物认证的系统和方法
公开(公告)号：US08433922B2
公开(公告)日：2013-04-30
申请号：US12873729
申请日：2010-09-01
申请人： Yosuke Kaga , Osamu Takata , Yoshiaki Isobe , Kenta Takahashi , Takao Murakami
发明人： Yosuke Kaga , Osamu Takata , Yoshiaki Isobe , Kenta Takahashi , Takao Murakami
IPC分类号： G06F21/00 , G06K9/00
CPC分类号： G06F21/32 , G06F2221/2117
摘要： In additional enrollment of a template in a biometric authentication system, the template is automatically enrolled on the basis of a plurality of authentication results to assure a user's convenience and security. A post-migration authentication server receives a first template and a second template from a post-migration authentication terminal, performs authentication on the basis of the comparison result between the received first template and the user's preliminarily first enrolled template, and provisionally enrolls the first template and the second template. It repeats the reception, authentication, and provisional enrollment and calculates a match probability from a plurality of comparison results of the provisionally first enrolled templates, determines whether or not to store a second enrolled template on the basis of the match probability, and automatically enrolls the second template in the post-migration authentication server.
摘要翻译：在生物认证系统中额外登记模板时，基于多个认证结果自动注册该模板，以确保用户的便利性和安全性。迁移后认证服务器从迁移后认证终端接收第一模板和第二模板，根据接收到的第一模板与用户的初始登录模板之间的比较结果进行认证，并临时登记第一模板和第二个模板。它重复接收，认证和临时注册，并根据临时第一登记模板的多个比较结果计算匹配概率，基于匹配概率确定是否存储第二登记模板，并自动注册后迁移认证服务器中的第二个模板。

33. 发明授权

US08312521B2 Biometric authenticaton system and method with vulnerability verification 失效
标题翻译：生物识别验证系统和方法进行漏洞验证
公开(公告)号：US08312521B2
公开(公告)日：2012-11-13
申请号：US12293470
申请日：2007-03-23
申请人： Yoshiaki Isobe , Masahiro Mimura
发明人： Yoshiaki Isobe , Masahiro Mimura
IPC分类号： H04L29/00
CPC分类号： G06F21/32 , G06F21/51 , G06F21/577 , G06F2221/2101 , H04L9/3231
摘要： A biometric authentication device has a threat of an attack of pretending to be someone else by such as forgery. The present invention supports a service provider to appropriately decide the level of such threat.A vulnerability verification server 150 is provided in the system, and the vulnerability of each biometric product is centrally managed. A service provider 130 sends the information that specifies the device in which a client terminal 110 executes the biometric authentication to the vulnerability verification server 150, and receives the vulnerability information. The service provider 130 decides whether the service can be provided or not to the client terminal 110 using the vulnerability information that was received.
摘要翻译：生物识别认证设备有伪装的假冒伪装的威胁。本发明支持服务提供商适当地确定这种威胁的程度。系统中提供了一个漏洞验证服务器150，并且集中管理每个生物特征产品的漏洞。服务提供者130将指定客户终端110的设备的信息发送到漏洞验证服务器150，并接收该漏洞信息。服务提供者130使用接收到的漏洞信息来判定是否可以向客户终端110提供服务。

34. 发明授权

US06747564B1 Security guarantee method and system 失效
标题翻译：安全保障方法和制度
公开(公告)号：US06747564B1
公开(公告)日：2004-06-08
申请号：US09604918
申请日：2000-06-28
申请人： Masahiro Mimura , Yoichi Seto , Yoshiaki Isobe , Masaji Aoki
发明人： Masahiro Mimura , Yoichi Seto , Yoshiaki Isobe , Masaji Aoki
IPC分类号： G08C1900
CPC分类号： G07C9/00087 , H04L63/0853 , H04L63/105 , H04L63/107
摘要： A security system wherein, when a staff enters a building, a smart card carried by the staff is verified, and staff information inclusive of a staff number and fingerprint information is read from the smart card and is stored temporarily in a temporary storage file. When the staff logs on to a terminal, the fingerprint of the staff is read by a fingerprint input device (LS) and verified with the fingerprint information of the temporary storage file for verification. When the staff leaves the building, the staff number is read from the smart card the staff carries, and the corresponding staff information is erased from the temporary storage file. Security of a security object inside a security zone can be improved.
摘要翻译：一种安全系统，其中，当工作人员进入建筑物时，验证由工作人员携带的智能卡，并且从智能卡读取包括工作人员编号和指纹信息的工作人员信息，并临时存储在临时存储文件中。当员工登录终端时，由指纹输入设备（LS）读取员工的指纹，并用临时存储文件的指纹信息进行验证。当员工离开大楼时，从员工携带的智能卡读取员工人数，相应的员工信息从临时存储文件中删除。可以提高安全区域内的安全对象的安全性。

35. 发明授权

US5602140A Purine derivatives and suppressants for inflammatory diseases 失效
标题翻译：嘌呤衍生物和抑制剂用于炎性疾病
公开(公告)号：US5602140A
公开(公告)日：1997-02-11
申请号：US410838
申请日：1995-03-27
申请人： Yoshiaki Isobe , Nobuyoshi Chiba , Yuso Goto , Hideharu Sato
发明人： Yoshiaki Isobe , Nobuyoshi Chiba , Yuso Goto , Hideharu Sato
IPC分类号： C07D233/90 , C07D473/30 , A61K31/52
CPC分类号： C07D473/30
摘要： Purine derivatives shown by general formula [I] or pharmacologically acceptable salts thereof. Suppressants for inflammatory diseases containing an effective ingredient of said purine derivative. ##STR1## (wherein, R represents one group selected from the groups composed of H atom, a straight chain alkyl group having 1-10 carbon atoms, a branched chain alkyl group having 3-10 carbon atoms, an alkyl group having 1-10 carbon atoms substituted with one carboxyl group, 4-carboxybenzyl group and phenethyl group).Above mentioned purine derivatives prevent the tissue damages due to mediators such as active oxygen and TXA.sub.2 in the initial stage of inflammation, and prevent the subsequent aggravation of inflammatory responses due to the adhesion of activated leukocytes to the cells in the lesion, and exhibit efficacy as anti-inflammatory drugs in all stages of inflammatory diseases caused by leukocytes.
摘要翻译：由通式[I]表示的嘌呤衍生物或其药理学上可接受的盐。含有所述嘌呤衍生物的有效成分的炎性疾病抑制剂。（I）（I）（其中，R表示选自由H原子，具有1-10个碳原子的直链烷基，具有3-10个碳原子的支链烷基组成的基团中的一个基团， 1-10个碳原子被一个羧基取代，4-羧基苄基和苯乙基）。上述嘌呤衍生物可防止炎症初期由于诸如活性氧和TXA2等介质而导致的组织损伤，并且防止由于活化的白细胞粘附于病变中的细胞而导致的炎性反应的随后恶化，抗炎药物在白细胞引起的炎症性疾病的各个阶段。

36. 发明授权

US08412940B2 Biometric authentication method and system 有权
标题翻译：生物识别方法和系统
公开(公告)号：US08412940B2
公开(公告)日：2013-04-02
申请号：US13057468
申请日：2009-08-21
申请人： Kenta Takahashi , Shinji Hirata , Yoshiaki Isobe
发明人： Kenta Takahashi , Shinji Hirata , Yoshiaki Isobe
IPC分类号： H04L29/06
CPC分类号： H04L63/0861 , G06F21/32 , G06F21/83 , G06F2221/2153 , G06K2009/00953 , G07C9/00158 , G07C9/00166 , G07C2209/12 , H04L9/3231 , H04L2209/043
摘要： At registration time, feature data array for registration is generated from biometric information, and position correction template and comparison template. At authentication time, feature data array for authentication is generated from biometric information acquired by the client, and converted feature data for position correction obtained by converting the feature data array for authentication is transmitted to the server. The server detects position correction amount of the feature data array for authentication relative to the feature data array for registration using the position correction template and the converted feature data, and transmits the position correction amount to client. Client corrects the feature data array for authentication and transmits the converted feature data array for comparison to the server. Server calculates a distance between the comparison template and the converted feature data array for comparison and determines success or failure of the authentication on the basis of the distance.
摘要翻译：在注册时，从生物特征信息和位置校正模板和比较模板生成用于注册的特征数据阵列。在验证时，由客户端获取的生物特征信息生成用于认证的特征数据阵列，并将用于认证的特征数据阵列转换获得的用于位置校正的转换特征数据发送到服务器。服务器使用位置校正模板和转换的特征数据来检测用于认证的特征数据阵列的位置校正量，并且将位置校正量发送给客户端。客户端更正特征数据阵列进行认证，并将转换的特征数据数组发送到服务器进行比较。服务器计算比较模板和转换的特征数据数组之间的距离进行比较，并根据距离确定认证的成功或失败。

37. 发明申请

US20100298364A1 SALTS 756 有权
公开(公告)号：US20100298364A1
公开(公告)日：2010-11-25
申请号：US12784226
申请日：2010-05-20
申请人： Nicholas James BENNETT , Thomas McInally , Austen Pimm , Stephen Thom , Yoshiaki Isobe
发明人： Nicholas James BENNETT , Thomas McInally , Austen Pimm , Stephen Thom , Yoshiaki Isobe
IPC分类号： A61K31/505 , C07D239/48 , A61P11/06 , A61P35/00 , A61P31/18 , A61P31/20 , A61P31/04 , A61P31/14 , A61P17/00
CPC分类号： C07D239/49 , C07D275/06
摘要： The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：本发明提供2-（4 - （（2-氨基-4-甲基-6-（戊基氨基）嘧啶-5-基）甲基）苯基）乙酸4-（二甲基氨基）丁酯的盐，含有它们的药物组合物及其用途在治疗。

38. 发明授权

US06376501B1 Type 2 helper T cell-selective immune response suppressors 失效
标题翻译： 2型辅助性T细胞选择性免疫应答抑制剂
公开(公告)号：US06376501B1
公开(公告)日：2002-04-23
申请号：US09582176
申请日：2000-06-21
申请人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Hiroyuki Matsui , Hideyuki Tomizawa
发明人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Hiroyuki Matsui , Hideyuki Tomizawa
IPC分类号： A61K3152
CPC分类号： A61K31/522 , A61K31/52 , C07D473/00 , C07D473/34
摘要： The present invention relates to a type 2 helper T cell-selective immune response inhibitor, an immune response regulator and an anti-allergic agent, individually comprising, as an active ingredient, a purine derivative represented by General Formula (I): wherein R2 is hydrogen or a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; R6 is hydroxyl, amino or amino which is mono- or di-substituted by a hydrocarbon group(s); R8 is hydroxyl, mercapto, acyloxy or hydrocarbon group-substituting oxycarbonyloxy; and R9 is a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; or its tautomer or a salt of the purine derivative or the tautomer.
摘要翻译：本发明涉及一种2型辅助性T细胞选择性免疫应答抑制剂，免疫应答调节剂和抗过敏剂，其各自包含作为活性成分的由通式（I）表示的嘌呤衍生物：其中R 2为氢或其中不直接结合嘌呤骨架的-CH 2可以被CO，SO 2，O或S取代的烃基，并且不直接键合到嘌呤骨架上的CH可以被N，C-卤素或C-CN R6是羟基，被一个或多个烃基单取代或二取代的氨基或氨基; R8是羟基，巯基，酰氧基或烃基取代的氧羰基氧基; 并且R 9是其中不直接结合嘌呤骨架的-CH 2可以被CO，SO 2，O或S取代的烃基，并且不直接键合到嘌呤骨架上的CH可以被N，C-卤素或C- CN;或其互变异构体或嘌呤衍生物或互变异构体的盐。

39. 发明授权

US06310070B1 Purine derivatives and medicinal use thereof 失效
标题翻译：嘌呤衍生物及其药用
公开(公告)号：US06310070B1
公开(公告)日：2001-10-30
申请号：US09462861
申请日：2000-04-28
申请人： Akihisa Yokoyama , Sumitsugu Kisanuki , Yoshikazu Matsuda , Junko Matsui , Yoshiaki Isobe
发明人： Akihisa Yokoyama , Sumitsugu Kisanuki , Yoshikazu Matsuda , Junko Matsui , Yoshiaki Isobe
IPC分类号： C07D47330
CPC分类号： C07D473/30
摘要： A novel purine derivative exhibiting an effect to control inflammatory symptoms characteristic to nephritis and a medicine comprising this compound as an effective ingredient are provided. The compound is represented by the following general formula (I), wherein R1 is a hydrocarbon group having 17 or less carbon atoms and R2 is a hydrocarbon group having 16 or less carbon atoms, wherein one or more CH2 g roups in the hydrocarbon group which 7013 do not directly bind with the carbon atom at 2 or 7 position of the purine ring replaced are by carbonyl groups, sulfonyl groups, O, or S and/or one or more CH groups in the hydrocarbon group which do not directly bind with the carbon atom at 2 or 7 position of the purine ring are replaced by N, C-halogen, or C—C≡N, or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了具有控制肾炎特征性炎症症状的效果的新型嘌呤衍生物和含有该化合物作为有效成分的药物。该化合物由以下通式（I）表示，其中R 1是具有17个或更少碳原子的烃基，R 2是具有16个或更少碳原子的烃基，其中一个或多个在烃基中的CH 2 7013不与嘌呤环的2或7位的碳原子直接结合，所取代的碳原子是羰基，磺酰基，O或S和/或烃基中一个或多个不与直接键合的CH基团嘌呤环2或7位的碳原子被N，C-卤素或CC = N取代，或其药学上可接受的盐。

40. 发明授权

US5821247A Hydroquinone derivative and pharmaceutical use thereof 失效
标题翻译：对苯二酚衍生物及其药物用途
公开(公告)号：US5821247A
公开(公告)日：1998-10-13
申请号：US933208
申请日：1997-09-16
申请人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
发明人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
IPC分类号： C07D239/54 , C07D239/545 , C07D405/12 , A61K31/51
CPC分类号： C07D239/545 , C07D405/12
摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group; R.sup.2 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group; R.sup.5 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group; P is a hydroxyl group; Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group; P may form together with Q an ether bond; R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group; X is a single bond, an --NR.sup.10 --group or a --CH.sub.2 --NR.sup.10 --group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group; Y is a methylene group or a carbonyl group; and dotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
摘要翻译：公开了氢醌衍生物或其药学上可接受的盐，所述对苯二酚衍生物由式（I）表示：未取代的或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式